Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 22, 2011
CYTOSORBENTS CORPORATION
(Exact name of registrant as specified in its charter)
|
Nevada
|
|
000-51038
|
|
98-0373793
|
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification Number)
|
7 Deer Park Drive, Suite K
Monmouth Junction, New Jersey 08852
(Address of principal executive office) (Zip Code)
(732) 329-8885
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
On June 22, 2011, Cytosorbents Corporation (the “Company”) posted the following information on its website: (i) a letter to all shareholders in an effort to provide an update on recent accomplishments; (ii) an investor presentation; and (iii) an executive summary. Copies of this information are attached hereto as Exhibits 99.1, 99.2 and 99.3, respectively.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statement and Exhibits.
|
(a)
|
Financial statements of business acquired.
|
| |
Not applicable.
|
| |
|
|
(b)
|
Pro forma financial information.
|
| |
Not applicable.
|
| |
|
|
(c)
|
Shell company transactions.
|
| |
None.
|
| |
|
|
(d)
|
Exhibits.
|
|
99.1
99.2
99.3
|
Letter to Shareholders
Investor Presentation
Executive Summary
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Cytosorbents Corporation
|
|
| |
|
|
|
| |
By:
|
/s/ David Lamadrid
|
|
| |
|
Name: David Lamadrid
|
|
| |
|
Title: Chief Financial Officer
|
|
Dated: June 27, 2011